Congratulations to our co-founder and chief technology officer Sourav Bandyopadhyay, Ph.D., for recently making In Vivo’s 2024 Rising Leaders list! As Rezo's very first employee, Sourav has played a key role in Rezo's growth and development as we aim to use the integrated mapping of disease networks for precision therapeutics. Read more about the role Sourav plays in the link below. Congrats, Sourav!
Rezo Therapeutics
Biotechnology Research
San Francisco, California 1,591 followers
Revolutionizing Drug Discovery by Mapping Biological Networks
About us
Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. Our Founders and members of the Board are a group of esteemed, world-class scientists from the University of California, San Francisco: Nevan Krogan, Kevan Shokat, Sourav Bandyopadhyay, Natalia Jura, as well as renowned biotech executives George Scangos and Norbert Bischofberger. These leaders bring with them a strong track record of amazing discoveries and scientific breakthroughs, leading to very successful companies and many FDA approved drugs.
- Website
-
www.rezotx.com
External link for Rezo Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Francisco, California
- Type
- Privately Held
Locations
-
Primary
Get directions
455 Mission Bay Blvd S
San Francisco, California 94158, US
Employees at Rezo Therapeutics
Updates
-
Congrats are in order for our head of operations and program management, Krystal Fontaine, PhD, PMP, who was recently included as one of San Francisco Business Times' top Next Generation of Women Researchers in Life Sciences. It's no secret to those of us who have the pleasure of working with Krystal every day that she is a superstar well beyond her years and we are incredibly lucky to have her talents at Rezo. Congrats, Krystal! Read more about Krystal's professional experiences and rise to leadership in the feature below.
These are the next generation of biotech superstars in the Bay Area - San Francisco Business Times
bizjournals.com
-
Rezo is excited to be included among BioSpace's NextGen Class of 2024! 2023 was an important year for Rezo and we look forward to carrying that same momentum into the new year as we seek to unlock a new era of #drugdiscovery. Check out the entire list of recipients below.
NextGen Class of 2024: Top Life Sciences Startups to Watch This Year | BioSpace
biospace.com
-
We are incredibly proud to announce the publishing of research findings today by Quantitative Biosciences Institute, UCSF that demonstrate the powerful approach of our platform technology. This paper further emphasizes how an integrated approach to drug discovery through leveraging multiple technologies and tools can be applied across disease areas. Congratulations to our co-founder and president, Nevan Krogan, for his work surrounding this exciting scientific development. https://lnkd.in/gwBmrbxQ
-
“I love the big, risky, super transformational opportunity with a big vision... That's what gets me motivated.” Thank you Max Bayer and Fierce Biotech for the great piece highlighting the addition of Nadir Mahmood, Ph.D., as our CEO. Hear what he and Rezo co-founder and president Nevan Krogan, Ph.D., had to say about the future of our approach in the article below.
Ex-Nkarta exec Nadir Mahmood rises to first CEO role at UCSF spinout Rezo
fiercebiotech.com
-
We're excited to welcome Nadir Mahmood, Ph.D., to Rezo as chief executive officer and board member! This appointment spotlights the strong progress we've made to advance our leading protein-protein interaction platform and the potential opportunity to fundamentally shift the way we understand disease biology through our integrated mapping of disease networks for precision therapeutics. Learn more about Dr. Mahmood below. https://lnkd.in/gBfTXKXe